Pimavanserin and Aggression and Social Cognition.
Intermittent Explosive Disorder
About this trial
This is an interventional basic science trial for Intermittent Explosive Disorder focused on measuring Aggression, Intermittent Explosive Disorder, Hostile Social Cognition, 5-HT-2a Receptor Antagonist, Pimavanserin
Eligibility Criteria
Inclusion Criteria: Participants will have a current (or past) DSM-5 diagnosis of Intermittent Explosive Disorder (IED). In addition, all participants must meet the following criteria: Participant is between 21 and 55 years of age and is able to give informed consent. Participant is physically healthy as confirmed by medical history, physical evaluation, ECG, and (in females) has a negative pregnancy test. Four weeks free of psychotropic medication. (Please note that only 10% of screened subjects take psychotropics of any kind because we recruit from the general community and such individuals are much less likely to be under psychiatric care at the time of recruitment; we do not take patients off their medication to enroll them in studies; such patients are referred for clinical treatment instead). Exclusion Criteria: All subjects with the following are excluded from study: Clinically significant medical condition. Prolonged QT-Interval ( > 0.45 / > 0.47 seconds for males/females). Life history of bipolar disorder / schizophrenia / organic mental syndrome or intellectual disability. Current major depressive disorder with a BDI score > 32. Current alcohol / drug use disorder of greater than mild severity. Current suicidal ideation. Allergy, or other contraindication, to pimavanserin. Current treatment with opiates or any agents that affect pain threshold. Unwilling/unable to sign informed consent document.
Sites / Locations
- The Ohio State University College of Medicine
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Pimavanserin
Placebo
One single dose of pimavanserin (34 mg oral)
One single dose of matching placebo